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ABSTRACT
The less processed forms of gastrin have recently been shown to act as
trophic factors for both normal and malignant colonic cells. Although
incompletely processed forms of gastrin such as glycine-extended gastrin
and progastrin are also expressed in human lung cancers, the clinical
significance of this expression has not been addressed. Consequently, we
investigated the effects of overexpression of glycine-extended gastrin in a
mouse strain that is prone to developing lung cancer and also examined
the expression of incompletely processed gastrins in primary human lung
cancers. We found that transgenic overexpression of glycine-extended
gastrin in FVB/N mice resulted in a significant increase in the prevalence
and growth of bronchoalveolar carcinoma. In addition, a substantial
subset of human lung cancers was found to express progastrin and/or
glycine-extended gastrin. Overexpression of glycine-extended gastrin by
human lung cancers was associated with a significantly decreased sur-
vival. Taken together, these results suggest that glycine-extended gastrin
may play a role in the growth and progression of some human lung
cancers.
INTRODUCTION
Worldwide, lung cancer is the leading cause of cancer-related
mortality. In the United States, lung cancer represents the leading
cause of death from cancer with an estimated 171,500 new cases in
1998, resulting in 165,500 deaths (1). Over 40,000 new cases are
diagnosed each year in the United Kingdom (2). Unfortunately, by the
time lung cancer is detected, it is often difficult to treat, resulting in
poor (14% in the United States and 5% in the United Kingdom)
5-year survival rates (2, 3). A better understanding of the genes
involved in the pathogenesis of lung cancer would theoretically lead
to novel therapeutic targets in the treatment of lung cancer. The
development of lung cancer, as with many other cancers, is a multi-
stage process involving alterations in multiple oncogenes (e.g., K-ras),
tumor suppressor genes (e.g., p53), and DNA mismatch repair genes
(e.g., MSH1, hMLH1, and MSH2; Refs. 4–7). However, although
several of these early genetic changes have been well studied, many
of the downstream targets of these signaling pathways have been less
thoroughly examined. Some of these downstream targets are growth
factors (such as epidermal growth factor, transforming growth factor
, and platelet-derived growth factor) secreted by lung epithelial cells,
as well as a variety of neuropeptides such as bombesin/gastrin-
releasing peptide (particularly in small cell lung cancer), vasopressin,
bradykinin, neurotensin, and gastrin (8).
It has long been recognized that gastrin in its amidated form is an
important regulator not only of acid secretion but also mucosal
growth, primarily for the fundic mucosa of the stomach (9, 10).
Gastrin has been shown to function as a growth factor for the gastro-
intestinal mucosa in vivo and for gastric cancer cell lines in vitro.
However, it is likely that gastrin has important growth factor functions
outside of the gastrointestinal tract. For example, it has previously
been shown that gastrin is also expressed in the majority of human
lung cancers (11). Although the biological significance of gastrin
expression in lung cancer has not yet been fully elucidated, early
studies have been intriguing. Zhou et al. (12) reported that patients
with small cell carcinoma, adenocarcinoma, and squamous cell car-
cinoma of the lung had elevated levels of gastrin in both their serum
as well as in their bronchoalveolar lavage fluid compared with normal
controls. In addition, they found that elevated serum gastrin levels
correlated with worse prognosis; in addition, gastrin levels fell after
curative resection and became elevated again in the setting of new
metastases (13). In contrast, other studies have shown no prognostic
value for gastrin measurements in the serum or bronchoalveolar
lavage fluid in lung cancer patients (14).
Lung cancers, as with most malignancies, lack the neuroendocrine-
processing enzymes to make the fully processed amidated form of
gastrin. Thus, the vast majority of gastrin synthesized by lung cancers
is in the form of the less-processed gastrin intermediates, progastrin,
and glycine-extended gastrin (11). Interestingly, it has also been
demonstrated that normal lung tissue expresses very low levels of
these gastrin-processing intermediates (11). Although in the past it
was assumed that incompletely processed gastrins possessed no bio-
logical function, more recent studies have shown that these less
processed forms of gastrin can act as growth factors for the normal
colon (15–17), as well as gastrointestinal cell lines (18, 19). Although
additional work is required to characterize relevant receptors, it is
clear that progastrin and glycine-extended gastrins have low affinity
for the gastrin-CCK-B (CCK-2) receptor.
Furthermore, recent studies have suggested that the less processed
forms of gastrin play a role in the pathogenesis of colorectal cancer.
Transgenic mice that overexpress progastrin are more prone to colon
carcinomas induced by azoxymethane than wild-type controls (20,
21). Mice that have elevated serum levels of glycine-extended gastrin
through either infusion or insertion of a transgene are more prone to
intestinal polyposis in the APC min mouse model (22, 23), whereas
gastrin deficiency generated by either homologous recombination or
through an immunogen that raises a gastrin-immunoneutralizing an-
tibody results in a decreased number of polyps in the APC min mouse
model (22, 23). Finally, it has been shown that glycine-extended
gastrin can promote the invasiveness of human colon cancer cells
(24).
Interestingly, we found that transgenic mice overexpressing
glycine-extended gastrin (MTI/G-Gly) also spontaneously develop
occasional bronchoalveolar carcinomas at 1 year of age (25). These
tumors occurred in a genetic background (FVB) that has been reported
to show spontaneous development of lung cancer (26). To explore
fully the role of gastrin in the pathogenesis of lung cancer, we
analyzed further the MTI/G-Gly mice in terms of tumor prevalence,
tumor burden, and proliferation rates compared with wild-type FVB
Received 7/15/03; revised 10/2/03; accepted 10/20/03.
Grant support: NIH Grants K08 DK02545 and R03 DK60225-01 (T. J. K.) and RO1
DK52779 (T. C. W.). The Roy Castle Foundation UK supported T. L. and P. F., and the
Medical Research Council supported A. V. and G. J. D.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
Note: T. J. Koh and J. K. Field contributed equally to this work.
Requests for reprints: Timothy C. Wang, Division of Gastroenterology, University of
Massachusetts Medical Center, Lazare Research Building, Room 208, 364 Plantation
Street, Worcester, MA 01605-2324. Phone: (508) 856-4778; Fax: (508) 856-4770; E-mail:
timothy.wang@umassmed.edu.
196
mice. In addition, we correlated these findings with expression pat-
terns in human lung cancer specimens.
MATERIALS AND METHODS
Generation of MTI/G-Gly Mice. A mouse metallothionein promoter-
human glycine-extended gastrin cDNA transgene was used to generate trans-
genic mice that overexpress glycine-extended gastrin in the FVB background
as described previously (25). This transgene resulted in elevated levels of
glycine-extended gastrin at the RNA level in all tissues examined (colon,
kidney, liver, lung, pancreas, and stomach) and of peptide in the serum, with
the predominant circulating form being G34-Gly. One line (7483) was primar-
ily used for this study, although lung cancers were noted in all four MT/G-
Gly-transgenic lines that were generated (25).
Animals were housed in microisolator, solid-bottomed polycarbonate cages
and fed a commercially prepared pelleted diet and given water ad libitum. The
mice were all maintained in an Association for Assessment and Accreditation
of Laboratory Animal Care-approved facility under barrier conditions as virus
antibody free mice for the duration of the experiment. The protocol was
approved by the animal care committee (Institutional Animal Care and Use
Committee) of the University of Massachusetts Medical School.
Analysis of Murine Lung Tumors. Nineteen MTI/G-Gly mice and an
equal number of strain-matched (FVB) control mice were sacrificed at 18
months. Twelve MTI-G-Gly mice and 16 FVB mice were sacrificed at 12
months. The lung tissue was then either fixed in 4% paraformaldehyde over-
night for eventual embedding with paraffin or in OCT compound and frozen on
dry ice. Blocks were sectioned at 5 m for histological and immunohisto-
chemical analysis and thoroughly examined for lung lesions. A minimum of
five sections were examined for each lung. Routine H&E staining was per-
formed for all sacrificed mice, and the number of tumors/lung was quantified
according to size and histological phenotype. Ductular hyperplasia/dysplasia is
defined as a hyperproliferative state of the bronchial epithelium with or
without the presence of dysplastic cells (as evidenced by cytological atypia,
loss of nuclear polarity, increased nuclear to cytoplasmic ratio, increased
basophilic staining of the nucleus, and increased number of mitoses) with
preservation of the underlying bronchial architecture. Adenomas were defined
as a circumscribed lesion maintaining glandular architecture lined by dysplas-
tic epithelium that distorts the underlying bronchial architecture. Adenocarci-
nomas were defined as macroscopically apparent lesions (5 mm) with
invasion of neoplastic cells into surrounding structures, including blood and/or
lymphatic vessels.
Patients. Tumor samples were obtained from consenting patients undergo-
ing surgical resection for lung cancer at the Cardiothoracic Centre Liverpool
NHS Trust. A diagnosis of squamous carcinoma of the lung was made in 109
patients (mean age, 65.5 years; range, 42.7–87.5 years) and adenocarcinoma of
the lung in 143 (mean age, 67.1 years; range, 48.8–82.6 years). This study was
undertaken with ethical approval. The specimens formed part of an archival
collection.
Immunohistochemistry. For murine tissues, proliferating cell nuclear an-
tigen staining was performed from paraffin-embedded sections from all slides
where tumors were found, sectioned at 5 m, and then deparaffinized in xylene
through alcohol. The slides were then placed in 2 M HCl for 1 h at room
temperature. The slides were washed in PBS, incubated with horse serum for
30 min, washed again in PBS, and then underwent incubation with a mouse
proliferating cell nuclear antigen antibody (working dilution 1:100; DAKO-
PATTS, Copenhagen, Denmark) and then stained using the Animal Research
Kit (DAKOPATTS). The proliferating cell nuclear antigen labeling index was
determined as the number of immunopositive cells multiplied by 100 and
divided by the total number of cells/high-powered field in either tumors or
surrounding normal tissue.
For human studies, samples obtained from paraffin-embedded tissue blocks
were arrayed in a 20  20 grid (27, 28) and included positive controls of
duodenum and stomach (Fig. 3, A–F). Sections were processed using antibod-
ies reacting selectively with the main products of the gastrin gene. Antibody
L382 was raised to a COOH-terminal sequence of human preprogastrin (93–
101; i.e., GRRSAEDEN); it reacts with progastrin and its COOH-terminal
fragments but not with glycine-extended or amidated gastrins, which do not
share this epitope. Antibody L373 was raised to the peptide EEAYGWMDFG
corresponding to human preprogastrin 84–93; absorption controls using this
peptide, G17, and COOH-terminal progastrin fragments indicate that this
antibody reacts with the COOH-terminal Gly-extended gastrins but not
progastrin or amidated gastrins. Antibody L425 is directed at the common
COOH-terminal amidated sequence shared by the amidated gastrins and cho-
lecystokinin, and absorption controls indicate that it does not react with
Fig. 1. Lung histopathology in MT1/G-Gly transgenic mice. MTI/G-Gly mice were
followed for 12–18 months and then sacrificed, and their lungs were processed for
histology. Lesions were scored according to standard pathological criteria (see “Materials
and Methods”). This revealed the presence of areas of ductal hyperplasia/dysplasia
(magnification, 200; A), alveolar adenoma (magnification, 200; B), and bronchoal-
veolar carcinoma (magnification, 200; C).
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glycine-extended gastrins or progastrin. Endogenous peroxide was blocked
with 3% hydrogen peroxide and nonspecific protein blocked with 10% goat
serum and 0.25% BSA in 0.05 M Tris-HCl. Primary antibodies were used for
1 h at dilutions of 1:1500 for L382 and 1:1000 for L373 and the Sako LSAB2
HRP labeling kit was used with diaminbenzidine substrate and hematoxylin
staining. Sections were screened independently by three observers, including
one highly experienced pathologist. The criteria for positive staining in the
specimens was staining found in 10% of the tumor cells.
Data Analysis. For the murine studies, statistical analysis was performed
using either the 2 test or a one-tailed Student’s t test. All results are expressed
as mean SE. For the human studies, all analyses were performed using SPSS
10.0 for Windows. Associations were assessed using the 2 and Kaplan Meier
for survival analysis. Survival analysis was calculated for the adenocarcinoma
specimens on the 63 individuals for whom we had follow-up data.
RESULTS
MTI/G-Gly Mice Have Significantly Higher Prevalence of Lung
Tumors. Transgenic mice overexpressing glycine-extended gastrin
(MTI/G-Gly) in both serum and the lung in the FVB mouse strain
have previously been described (25). These mice express gastrin at the
mRNA level in all tissues examined and have elevated circulating
levels of glycine-extended gastrin in the serum (85.0  28.0 pM)
compared with FVB mice (30 pM; Ref. 25). The MTI/G-Gly mice
developed ductular hyperplasia/dysplasia (Fig. 1A), alveolar adeno-
mas (Fig. 1B), and bronchoalveolar carcinoma (Fig. 1C), suggesting a
stepwise progression toward the development of bronchoalveolar car-
cinoma similar to that previously published in mice with somatic
activation of the k-ras oncogene (29, 30).
At both 12 and 18 months, the MTI-Gly mice had a significantly
higher prevalence of bronchoalveolar carcinoma than did the wild-
type controls (16.7 versus 0%, P  0.05 and 26.3 versus 10.5%,
P  0.05, respectively; Fig. 2A). Of the mice that developed bron-
choalveolar carcinoma at 18 months, the MTI-Gly mice also had a
higher tumor burden (number of cancers/mouse) when compared with
wild-type mice (2.0  0.63 versus 1.0  0.0, P  0.09). The tumors
of the MTI/G-Gly mice also had a higher proliferation rate as meas-
ured by proliferating cell nuclear antigen staining when compared
with the tumors found in the FVB mice (15.88  2.37 versus
6.83  0.45, P  0.05; Fig. 2B).
Expression of Gly-gastrin and Progastrin in Lung Cancer.
Immunostaining was then performed on primary human lung cancers
using antibodies against human progastrin, glycine-extended gastrin
or amidated gastrin (Tables 1 and 2). Antibodies reacting with pro-
gastrin (L382) and Gly-gastrin (L373) revealed consistent staining of
some tumors, but antibody to the COOH terminus of amidated gas-
trins did not show positive staining (Fig. 3, A–F). Of 143 samples of
adenocarcinoma, 64 were positive for progastrin and 26 for Gly-
gastrin. Of the latter, 16 were also progastrin positive but 10 were
progastrin negative (Table 2). In the case of squamous carcinoma, 56
of 109 samples were progastrin positive and 4 were Gly-gastrin
positive (Table 1). The expression of Gly-extended gastrins in ade-
nocarcinoma was significantly greater than in squamous carcinoma
(P  0.001). Interestingly, there was a statistically significant
(P  0.015) association between Gly-gastrin expression and de-
creased survival of adenocarcinoma patients (Fig. 4). The number of
squamous carcinoma patients expressing Gly-gastrin was insufficient
for an analysis. However, there was no difference in the survival of
either adenocarcinoma or squamous carcinoma patients expressing
progastrin compared with those not expressing progastrin (Fig. 4).
Progastrin Expression Correlates with More Immature Differ-
entiation Status of the Tumor. One hundred thirty-nine adenocar-
cinomas with confirmed pathological differentiation grades were an-
alyzed to ascertain whether either progastrin or glycine-extended
gastrin expression (or both) correlated with differentiation status of
the tumor (P  0.018). Positive staining was found in 24 of 50 poorly
differentiated, 34 of 74 moderately differentiated, and 1 of 14 well-
differentiated adenocarcinomas. This analysis revealed that adenocar-
cinomas that stain positively for progastrin were associated with a
poorer degree of differentiation when compared with tumors that did
not express progastrin (Table 3). Tumors that expressed glycine-
extended gastrin did not appear to have a significant shift in differ-
entiation status compared with those that did not express glycine-
extended gastrin.
DISCUSSION
In this study, we present evidence that glycine-extended gastrin can
contribute to the growth and progression of lung cancer. Expression of
glycine-extended gastrin was noted in a substantial subset (e.g.,
Fig. 2. MT1/G-Gly show increased lung epithelial proliferation and lung cancer
prevalence. A, prevalence of bronchoalveolar carcinomas in 12- and 18-month-old MTI/
G-Gly mice (f) compared with wild-type FVB mice ( ). B, proliferation rates as
determined from PCNA staining in MTI/G-Gly mice (f) compared with wild-type FVB
mice ( ).  indicates a significant increase in proliferation rate in the MT1/G-Gly mice
(P  0.05).
Table 1 Progastrin and G-Gly immunostaining in human squamous carcinoma of
the lung
L382  L382  Total
L373  2 2 4
L373  54 51 105
Total 56 53 109
Table 2 Progastrin and G-Gly immunostaining in human adenocarcinoma of the lung
L382  L382  Total
L373  16 10 26
L373  48 69 117
Total 64 79 143
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18%) of human lung adenocarcinomas. Although overexpression of
glycine-extended gastrin does not appear to change the differentiation
status of the adenocarcinomas, overexpression of glycine-extended
gastrin within the carcinoma does correlate with a significantly worse
mean survival. Finally, overexpression of glycine-extended gastrin in
a mouse strain that is prone to developing bronchoalveolar carcinoma
resulted in an increased prevalence and number of bronchoalveolar
carcinomas.
Tumors are known to secrete a variety of peptides and growth
factors that stimulate in an autocrine fashion their own growth, with
the secretion of gastrin-releasing peptide in small cell lung cancer
perhaps being the best example. Recent studies have suggested that
the less processed forms of gastrin, including glycine-extended gas-
trin, can act as trophic factors for normal tissue (10, 15, 16, 25), as
well as cancer cell lines and tumors (18, 19). Overexpression of both
progastrin and glycine-extended gastrin has been shown to induce
colonic hyperplasia and accelerate the development of colon cancer
(20–22). Although specific receptors have not yet been fully charac-
terized for the incompletely processed gastrins, recent studies from a
number of groups have shown that G-Gly can activate mitogen-
activated protein kinase and other signaling pathways in gastrointes-
tinal cells (31), whereas progastrin appears to active pp60c-Src kinase
(32). In addition, migratory effects of G-Gly have been reported on
mouse gastric epithelial (IMGE-5) cells (31). However, although a
Fig. 3. Expression of gastrin precursor peptides (progastrin and G-Gly) in human lung cancers. A total of 109 human squamous cell carcinomas and 143 human adenocarcinomas
of the lung was immunostained to detect progastrin expression (L382) and glycine-extended gastrin (L373). Tumors were determined to be positive if 10% stained positively and
to be negative if 10% of cells stained positively. A and B, positive staining of squamous cell carcinoma with L382. C, positive staining of adenocarcimona with L382. D, negative
staining of adenocarcimona with L373. E, positive staining of adenocarcimona with L373. F, positive staining of stomach mucosa with L382.
Fig. 4. Expression of G-Gly correlates with
decreased survival in patients with lung adenocar-
cinoma. Kaplan-Meier survival curves were drawn
up for progastrin and Gly-gastrin expression in
adenocarcinomas and squamous cell of the lung.
No difference was found in the survival of either
adenocarcinoma or squamous carcinoma patients
expressing progastrin (L382) compared with those
not expressing progastrin. There was a statistically
significant (P  0.015) association between Gly-
gastrin expression and decreased survival of ade-
nocarcinoma patients.
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role for gastrin in gastrointestinal tumorigenesis appears to be well
established, relatively less attention has been given to its role in other
epithelial tumors.
The expression of gastrin by lung cancer was first recognized in
1989 by Rehfeld et al. (11), but there has been little work with
respect to the functional significance of this association. With
respect to human lung cancer, there have been a number of mi-
croarray analyses that have been applied to tumor specimens with
the goal of predicting survival or tumor behavior (33). To date,
gastrin has not emerged as a major gene of interest from our
expression profiling studies (34); however, it is conceivable that
this association may have been missed because of posttranscrip-
tional regulation or more likely to the need for subset analysis. In
our studies, we were able to confirm the earlier reports that progastrin
and, to a lesser extent, glycine-extended gastrin, are expressed in human
lung cancers (11), and less than half of tumors were positive for either
peptide. In this investigation, adenocarcinomas that expressed progastrin
tended to have a more immature differentiation status, whereas only
patients with G-Gly-expressing tumors had a change in their mean
survival. It is worth pointing out that the poorly differentiated subgroup
only constituted 10% of the total number of adenocarcinomas analyzed so
that the correlation with differentiation should be treated with caution. In
this type of clinical analysis, survival data has to be considered the most
powerful clinical indicator, and we therefore place greater weight on the
relationship between G-Gly-expressing tumors and clinical outcome.
Although a number of hypergastrinemic mice have previously been
described, the MT1/G-Gly mice represent the first reported gastrin-
dependent model of lung adenocarcinoma. This propensity for lung
cancer development was confirmed in three independent MT1/G-Gly
lines and is no doubt related in part to the background genetic strain
(FVB/N) that is prone to developing bronchoalveolar carcinoma (26).
However, mice in our laboratory that overexpress human progastrin or
amidated gastrin (G17) in the FVB background do not appear to have
an increased frequency of lung bronchoalveolar carcinomas (data not
shown). Although these may suggest specificity of the lung cancer
pathway for G-Gly as opposed to G-17 or progastrin, caution is
needed in this interpretation because the MT1/G-Gly transgene not
only results in increased plasma levels of G-Gly but also is unique in
targeting gastrin expression specifically to the lung epithelium, raising
the possible need for autocrine action of this growth factor.
The MT1/G-Gly mouse model is similar in some respects to the
K-rasLA mouse, another mouse model of lung cancer that shows a
more rapid progression to neoplasia (29). In fact, gastrin overexpres-
sion in lung adenocarcinoma may be a direct consequence of onco-
genic ras mutations. Activating ras mutations have been reported to
occur in up to 50% of human adenocarcinomas (35) and in the large
majority of mouse lung tumors (36, 37). Furthermore, it has been
shown in colon cancer cell lines that activated ras can increase gastrin
expression (38), suggesting that the expression of gastrin seen in lung
cancers may be secondary to activating ras mutations. Future studies
may be needed to address the possible role of gastrin as a downstream
mediator of the Ras signaling pathway in tumorigenesis.
In summary, we find that overexpression glycine-extended gastrin
appears to increase the frequency of lung carcinomas in a transgenic
mouse model. The tumors from glycine-extended gastrin overexpress-
ing mice also have increased proliferation rates. Finally, a substantial
minority of human adenocarcinomas also overexpress glycine-ex-
tended gastrin, and the overexpression of glycine-extended gastrin
appears to be associated with a significantly decreased mean survival.
Taken together, this suggests that overexpression of glycine-extended
gastrin can play a physiological role in the pathogenesis of lung
adenocarcinoma and adds further weight to the therapeutic goal of
blocking glycine-extended gastrin in cancer patients.
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